M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.
Marco Ladetto,Monica Astolfi,Loredana Santo,Ilaria Avonto,Federica Cavallo,Gloria Pagliano,Patrizia Pregno,Mariella Grasso,Anna Marina Liberati,Tommaso Caravita,Francesco Pisani,Tommasina Guglielmelli,Elisa Genuardi,Rossana Crivelli,Carmen Cristiano,Daniela Drandi,Mario Boccadoro,Antonio Palumbo +17 more
TL;DR: In this paper, patients achieving CR or VGPR following an autologous transplantation-containing regimen were treated with an early consolidation regimen including Bortezomib, Thalidomide and Dexamethsone (VTD).
Journal ArticleDOI
Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone
Paula Rodriguez-Otero,Mario Boccadoro,Roman Hájek,Tomoaki Fujisaki,Jae Hoon Lee,Joaquin Martinez-Lopez,Paulo Sérgio Lucio,Zsolt Nagy,Ganna Usenko,Anna Marina Liberati,Mihaela Lazaroiu,Dariusz Woszczyk,Hiroyuki Takamatsu,Joanna Romejko-Jarosinska,Stefan Knop,Astrid Pavlovsky,Cecily Forsyth,Takayuki Ishikawa,Katharine S. Gries,Huiling Pei,Anupa Kudva,Jon Ukropec,Susan Wroblewski,Robin Carson,Meletios A. Dimopoulos +24 more
TL;DR: A PFS benefit with D-VMP vs VMP was observed in pts with a best response of PR, VGPR, and ≥CR; all patients who achieved ≥CR with MRD-negativity demonstrated prolonged PFS, regardless of treatment (Figure).
Journal ArticleDOI
MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
Elena Zamagni,Mario Boccadoro,Andrew Spencer,Michel Delforge,Donna E. Reece,Agoston Gyula Szabo,Hermann Einsele,Evangelos Terpos,Fredrik Schjesvold,Jelena Bila,Christoph Driessen,Meral Beksac,Gordon Cook,C A Rodríguez,Lixia Pei,Yingqi Shi,Caline Sakabedoyan,Jagaoda Jasielec,Himal Amin,Rachel Kobos,Pieter Sonneveld,N. W. C. J. van de Donk +21 more
TL;DR: The MajesTEC-4 trial as discussed by the authors evaluated the efficacy of a combination of Tec-Len and Lenalidomide (Len) as maintenance therapy in patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
Recombinant interferon-γ in a patient with multiple myeloma
Journal ArticleDOI
Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.
Antonio Palumbo,Sara Bringhen,Patrizia Falco,Cecilia Rus,Federica Cavallo,Maria Teresa Ambrosini,Ilaria Avonto,G Gallone,Tommaso Caravita,Benedetto Bruno,Mario Boccadoro +10 more
TL;DR: In this paper, the authors evaluated baseline demographic and clinical parameters to determine their value in predicting outcome of relapsed or refractory patients treated with Thalidomide and Dexamethasone (TD).